1420 related articles for article (PubMed ID: 26491824)
1. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women].
Musacchio MC; Cappelli V; Di Sabatino A; Morgante G; De Leo V
Minerva Ginecol; 2013 Feb; 65(1):89-97. PubMed ID: 23412023
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
Cappelli V; Di Sabatino A; Musacchio MC; De Leo V
Minerva Ginecol; 2013 Aug; 65(4):425-33. PubMed ID: 24051942
[TBL] [Abstract][Full Text] [Related]
4. Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients.
Stracquadanio M; Ciotta L; Palumbo MA
Gynecol Endocrinol; 2018 Jun; 34(6):495-501. PubMed ID: 29265900
[TBL] [Abstract][Full Text] [Related]
5. Myo-inositol vs. D-chiro inositol in PCOS treatment.
Formuso C; Stracquadanio M; Ciotta L
Minerva Ginecol; 2015 Aug; 67(4):321-5. PubMed ID: 25670222
[TBL] [Abstract][Full Text] [Related]
6. Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action.
De Cicco S; Immediata V; Romualdi D; Policola C; Tropea A; Di Florio C; Tagliaferri V; Scarinci E; Della Casa S; Lanzone A; Apa R
Gynecol Endocrinol; 2017 Sep; 33(9):698-701. PubMed ID: 28434274
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
Zacchè MM; Caputo L; Filippis S; Zacchè G; Dindelli M; Ferrari A
Gynecol Endocrinol; 2009 Aug; 25(8):508-13. PubMed ID: 19551544
[TBL] [Abstract][Full Text] [Related]
8. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
Pizzo A; Laganà AS; Barbaro L
Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome.
Fruzzetti F; Fidecicchi T; Palla G; Gambacciani M
Gynecol Endocrinol; 2020 Feb; 36(2):152-155. PubMed ID: 31317814
[TBL] [Abstract][Full Text] [Related]
10. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic approach for metabolic disorders and infertility in women with PCOS.
Morgante G; Massaro MG; Di Sabatino A; Cappelli V; De Leo V
Gynecol Endocrinol; 2018 Jan; 34(1):4-9. PubMed ID: 28850273
[TBL] [Abstract][Full Text] [Related]
12. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.
Minozzi M; Nordio M; Pajalich R
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):537-40. PubMed ID: 23467955
[TBL] [Abstract][Full Text] [Related]
13. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
Genazzani AD; Prati A; Marchini F; Petrillo T; Napolitano A; Simoncini T
Gynecol Endocrinol; 2019 Dec; 35(12):1088-1093. PubMed ID: 31304823
[TBL] [Abstract][Full Text] [Related]
14. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
Unfer V; Porcaro G
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
Zhao H; Xing C; Zhang J; He B
Reprod Health; 2021 Aug; 18(1):171. PubMed ID: 34407851
[TBL] [Abstract][Full Text] [Related]
16. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
Fruzzetti F; Capozzi A; Canu A; Lello S
Gynecol Endocrinol; 2019 Jun; 35(6):506-510. PubMed ID: 30612488
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
Fruzzetti F; Perini D; Russo M; Bucci F; Gadducci A
Gynecol Endocrinol; 2017 Jan; 33(1):39-42. PubMed ID: 27808588
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study.
Advani K; Batra M; Tajpuriya S; Gupta R; Saraswat A; Nagar HD; Makwana L; Kshirsagar S; Kaul P; Ghosh AK; Pradhan S; Mehta A; Jaiswal A; Nakhate KT; Kamdi S
J Obstet Gynaecol; 2020 Jan; 40(1):96-101. PubMed ID: 31339394
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
Schmidt TH; Khanijow K; Cedars MI; Huddleston H; Pasch L; Wang ET; Lee J; Zane LT; Shinkai K
JAMA Dermatol; 2016 Apr; 152(4):391-8. PubMed ID: 26720591
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
